Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treate...

Full description

Saved in:
Bibliographic Details
Published in:Asian Pacific journal of cancer prevention : APJCP 2014, Vol.15 (8), p.3537-3540
Main Authors: Seker, Mehmet Metin, Seker, Ayse, Aksoy, Sercan, Ozdemir, Nuriye, Uncu, Dogan, Zengin, Nurullah
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 3540
container_issue 8
container_start_page 3537
container_title Asian Pacific journal of cancer prevention : APJCP
container_volume 15
creator Seker, Mehmet Metin
Seker, Ayse
Aksoy, Sercan
Ozdemir, Nuriye
Uncu, Dogan
Zengin, Nurullah
description Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p
format article
fullrecord <record><control><sourceid>kisti</sourceid><recordid>TN_cdi_kisti_ndsl_JAKO201418342937043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JAKO201418342937043</sourcerecordid><originalsourceid>FETCH-kisti_ndsl_JAKO2014183429370433</originalsourceid><addsrcrecordid>eNqNyj0OgjAYANDGaCJR7tDFkYT-2OJIiMTggAODG6lQoLG2hq_cXwcP4PSWt0IR5VIkUtD7GkXkSFgimci2KAYwj5RzyVLBeYSqwhpnOv9WYfLWj6bDpVZhmTVg5Xp8m_3oPBjAfsA1BO1BzZ1_KWwcbpb5aWDCeb_YAHu0GZQFHf_coUN5bopL8j3BtK4H21b5taYp4SRjnJ6YTDlj_74PXU89fw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults</title><source>EZB Electronic Journals Library</source><creator>Seker, Mehmet Metin ; Seker, Ayse ; Aksoy, Sercan ; Ozdemir, Nuriye ; Uncu, Dogan ; Zengin, Nurullah</creator><creatorcontrib>Seker, Mehmet Metin ; Seker, Ayse ; Aksoy, Sercan ; Ozdemir, Nuriye ; Uncu, Dogan ; Zengin, Nurullah</creatorcontrib><description>Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p&lt;0.0001). Median overall survival (OS) was 80 months and 4 months, respectively (p=0.012). There were no survival differences in terms of presentation with pathological fracture, tumor size, tumor grade, alkaline phosphatase and lactate dehydrogenase level and type of chemotherapy regimen. Conclusions: Tumor site and stages are the most important prognostic factors for osteosarcoma. Extremity primary tumors have beter survival rates than non-extremity tumors. As a result of the use of effective chemotherapy the long term survival rates have improved from 10-20% to 60-70% in the last decades but we need more active agents, especially for metastatic cases.</description><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><language>kor</language><ispartof>Asian Pacific journal of cancer prevention : APJCP, 2014, Vol.15 (8), p.3537-3540</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,4010</link.rule.ids></links><search><creatorcontrib>Seker, Mehmet Metin</creatorcontrib><creatorcontrib>Seker, Ayse</creatorcontrib><creatorcontrib>Aksoy, Sercan</creatorcontrib><creatorcontrib>Ozdemir, Nuriye</creatorcontrib><creatorcontrib>Uncu, Dogan</creatorcontrib><creatorcontrib>Zengin, Nurullah</creatorcontrib><title>Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults</title><title>Asian Pacific journal of cancer prevention : APJCP</title><addtitle>Asian Pacific journal of cancer prevention : APJCP</addtitle><description>Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p&lt;0.0001). Median overall survival (OS) was 80 months and 4 months, respectively (p=0.012). There were no survival differences in terms of presentation with pathological fracture, tumor size, tumor grade, alkaline phosphatase and lactate dehydrogenase level and type of chemotherapy regimen. Conclusions: Tumor site and stages are the most important prognostic factors for osteosarcoma. Extremity primary tumors have beter survival rates than non-extremity tumors. As a result of the use of effective chemotherapy the long term survival rates have improved from 10-20% to 60-70% in the last decades but we need more active agents, especially for metastatic cases.</description><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNyj0OgjAYANDGaCJR7tDFkYT-2OJIiMTggAODG6lQoLG2hq_cXwcP4PSWt0IR5VIkUtD7GkXkSFgimci2KAYwj5RzyVLBeYSqwhpnOv9WYfLWj6bDpVZhmTVg5Xp8m_3oPBjAfsA1BO1BzZ1_KWwcbpb5aWDCeb_YAHu0GZQFHf_coUN5bopL8j3BtK4H21b5taYp4SRjnJ6YTDlj_74PXU89fw</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Seker, Mehmet Metin</creator><creator>Seker, Ayse</creator><creator>Aksoy, Sercan</creator><creator>Ozdemir, Nuriye</creator><creator>Uncu, Dogan</creator><creator>Zengin, Nurullah</creator><scope>JDI</scope></search><sort><creationdate>2014</creationdate><title>Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults</title><author>Seker, Mehmet Metin ; Seker, Ayse ; Aksoy, Sercan ; Ozdemir, Nuriye ; Uncu, Dogan ; Zengin, Nurullah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kisti_ndsl_JAKO2014183429370433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seker, Mehmet Metin</creatorcontrib><creatorcontrib>Seker, Ayse</creatorcontrib><creatorcontrib>Aksoy, Sercan</creatorcontrib><creatorcontrib>Ozdemir, Nuriye</creatorcontrib><creatorcontrib>Uncu, Dogan</creatorcontrib><creatorcontrib>Zengin, Nurullah</creatorcontrib><collection>KoreaScience</collection><jtitle>Asian Pacific journal of cancer prevention : APJCP</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seker, Mehmet Metin</au><au>Seker, Ayse</au><au>Aksoy, Sercan</au><au>Ozdemir, Nuriye</au><au>Uncu, Dogan</au><au>Zengin, Nurullah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults</atitle><jtitle>Asian Pacific journal of cancer prevention : APJCP</jtitle><addtitle>Asian Pacific journal of cancer prevention : APJCP</addtitle><date>2014</date><risdate>2014</risdate><volume>15</volume><issue>8</issue><spage>3537</spage><epage>3540</epage><pages>3537-3540</pages><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p&lt;0.0001). Median overall survival (OS) was 80 months and 4 months, respectively (p=0.012). There were no survival differences in terms of presentation with pathological fracture, tumor size, tumor grade, alkaline phosphatase and lactate dehydrogenase level and type of chemotherapy regimen. Conclusions: Tumor site and stages are the most important prognostic factors for osteosarcoma. Extremity primary tumors have beter survival rates than non-extremity tumors. As a result of the use of effective chemotherapy the long term survival rates have improved from 10-20% to 60-70% in the last decades but we need more active agents, especially for metastatic cases.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1513-7368
ispartof Asian Pacific journal of cancer prevention : APJCP, 2014, Vol.15 (8), p.3537-3540
issn 1513-7368
2476-762X
language kor
recordid cdi_kisti_ndsl_JAKO201418342937043
source EZB Electronic Journals Library
title Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A40%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kisti&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinicopathologic%20Features%20and%20Prognosis%20of%20Osteosarcoma%20in%20Turkish%20Adults&rft.jtitle=Asian%20Pacific%20journal%20of%20cancer%20prevention%20:%20APJCP&rft.au=Seker,%20Mehmet%20Metin&rft.date=2014&rft.volume=15&rft.issue=8&rft.spage=3537&rft.epage=3540&rft.pages=3537-3540&rft.issn=1513-7368&rft.eissn=2476-762X&rft_id=info:doi/&rft_dat=%3Ckisti%3EJAKO201418342937043%3C/kisti%3E%3Cgrp_id%3Ecdi_FETCH-kisti_ndsl_JAKO2014183429370433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true